Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA class I histocompatibility antigen, alpha chain E (HLA-E), functionally homologous to mouse Histocompatibility 2, T region locus 23 (H2-T23, encoding Qa-1b), is a non-classical MHC class Ib molecule. Unlike classical MHC class I molecules, HLA-E exhibits very limited polymorphism and primarily presents conserved signal sequence-derived peptides (such as VL9) to the inhibitory receptor CD94/NKG2A expressed on natural killer (NK) cells and CD8+ cytotoxic T lymphocytes. This interaction delivers a strong inhibitory signal that prevents immune-mediated lysis of healthy cells. However, many cancers overexpress HLA-E to exploit this pathway, effectively evading immune surveillance and resisting T-cell and NK-cell-mediated destruction. Consequently, the HLA-E/NKG2A axis has emerged as a major immune checkpoint and a highly promising therapeutic target in oncology. While clinical-stage antibodies like monalizumab target the NKG2A receptor, novel preclinical agents such as the monoclonal antibodies 3H4v31 and 4D7 directly target HLA-E or specific HLA-E/peptide complexes to block this inhibitory interaction and promote tumor clearance, sometimes additionally triggering antibody-dependent cellular cytotoxicity (ADCC).
Immune checkpoint inhibition by blocking the interaction between HLA-E and the inhibitory receptor CD94/NKG2A on NK cells and CD8+ T cells, thereby restoring antitumor immune responses and potentially inducing antibody-dependent cellular cytotoxicity (ADCC) against HLA-E-expressing tumor cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA class I histocompatibility antigen, alpha chain E (HLA-E).